A looming Medicare pay cut for hospitals will either devastate their ability to serve needy patients or will curb an out-of-control drug discount program, depending on whom you ask.
The pay cut, which would go into effect Jan. 1, would cut Medicare reimbursement for hospitals that use a separate program, known as 340B, to obtain discounted medications for outpatient care. The safety-net hospitals participating in 340B say the cuts to reimbursement, amounting to nearly 30 percent, would reduce access to care and wouldn’t help consumers, in contrast to what the Centers for Medicare & Medicaid Services has said would happen.
The CMS’s proposal from July would “tear a large hole in America’s healthcare safety net. We strongly urge HHS to drop it,” Ted Slafsky, the head of hospital group 340B Health, said in a statement. The CMS and its parent agency, the Department of Health & Human Services, have said the proposal was “a significant step toward fulfilling President Trump’s promise to address rising drug prices,” adding the proposal could reduce drug costs for seniors by at least an estimated $180 million per year.
A House Republican, Rep. Chris Collins (R-N.Y.), told me that the CMS’s decision “to rein in 340B spending is a good first step toward addressing the issues with this program, which are a result of its dramatic growth and lack of oversight since its inception.”
Collins said he’s “looking forward to further work by the Energy and Commerce Committee’s Oversight and Investigations Subcommittee as we continue our review of the 340B program and assure that it has the proper oversight, accountability and transparency.”
Meanwhile, congressional Republicans have asked 20 hospitals for details on their participation in 340B—a possible sign of legislative activity in this area.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)